<DOC>
	<DOCNO>NCT00441740</DOCNO>
	<brief_summary>The purpose study evaluate whether gemcitabine/vinorelbine combination versus gemcitabine/docetaxel combination first line treatment , offer survival advantage patient locally advanced/metastatic NSCLC .</brief_summary>
	<brief_title>Randomized Trial With Vinorelbine Gemcitabine Versus Docetaxel Gemcitabine Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Cisplatin-based chemotherapy represent backbone treatment advance NSCLC . However , several trial compare platinum versus non-platinum base chemotherapy regimen fail demonstrate statistically significant difference term time tumor progression survival . Newer agent gemcitabine , docetaxel vinorelbine show significant activity treatment NSCLC . Gemcitabine/vinorelbine combination first line treatment demonstrate response rate ( RR ) 18-43 % median overall survival ( OS ) 9.8-13 month . Similarly , gemcitabine/docetaxel combination show RR 32-35 % median OS 9-12 month . Given proven efficacy , combination two doublet , would interest .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm , unresectable locally advanced ( stage IIIB pleural effusion ) and/or metastatic ( stage IV ) NSCLC No previous therapy advanced/metastatic NSCLC allow Age &gt; 18 year Bidimensionally measurable disease Performance status ( WHO ) 02 Adequate liver ( serum bilirubin &lt; 1.5 time upper normal limit ( UNL ) ; AST ALT &lt; 2.5 time UNL absence demonstrable liver metastasis , &lt; 5 time UNL presence liver metastasis ) ; adequate renal function ( serum creatinine &lt; 1.5 time UNL ) ; bone marrow ( neutrophils ≥ 1.5x 109 /L , platelet ≥ 100x 109 /L ) function Previous radiotherapy , either adjuvant setting treatment metastatic disease allow provide measurable lesion outside radiation field Life expectancy 3 month Patient able take oral medication At least 4 week since prior radiotherapy Written inform consent Active infection History significant cardiac disease ( unstable angina , congestive heart failure , myocardial infarction within previous 6 month , ventricular arrhythmia ) Malnutrition ( loss ≥ 20 % original body weight ) Performance status : 34 Sensor motor neuropathy &gt; grade I Second primary malignancy , except nonmelanoma skin cancer Psychiatric illness social situation would preclude study compliance Pregnant lactate woman Known , symptomatic central nervous system metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>1st line treatment</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Vinorelbine</keyword>
	<keyword>Docetaxel</keyword>
</DOC>